These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17967159)

  • 1. Effect of consumer reporting on signal detection: using disproportionality analysis.
    Hammond IW; Rich DS; Gibbs TG
    Expert Opin Drug Saf; 2007 Nov; 6(6):705-12. PubMed ID: 17967159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety related drug-labelling changes: findings from two data mining algorithms.
    Hauben M; Reich L
    Drug Saf; 2004; 27(10):735-44. PubMed ID: 15350157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.
    Härmark L; van Hunsel F; Grundmark B
    Drug Saf; 2015 Apr; 38(4):337-47. PubMed ID: 25627832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.
    Matsushita Y; Kuroda Y; Niwa S; Sonehara S; Hamada C; Yoshimura I
    Drug Saf; 2007; 30(8):715-26. PubMed ID: 17696584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
    Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
    Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank.
    Caster O; Juhlin K; Watson S; Norén GN
    Drug Saf; 2014 Aug; 37(8):617-28. PubMed ID: 25052742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports.
    Liu R; Zhang P
    BMC Med Inform Decis Mak; 2019 Dec; 19(1):279. PubMed ID: 31849321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disproportionality analysis for signal detection of implantable cardioverter-defibrillator-related adverse events in the Food and Drug Administration Medical Device Reporting System.
    Duggirala HJ; Herz ND; Caños DA; Sullivan RA; Schaaf R; Pinnow E; Marinac-Dabic D
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):87-93. PubMed ID: 22095760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endotoxin-like reactions with intravenous gentamicin: results from pharmacovigilance tools under investigation.
    Hauben M; Reich L
    Infect Control Hosp Epidemiol; 2005 Apr; 26(4):391-4. PubMed ID: 15865275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A brief primer on automated signal detection.
    Hauben M
    Ann Pharmacother; 2003; 37(7-8):1117-23. PubMed ID: 12841826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.